公开(公告)号：US20130203741A1

公开(公告)日：2013-08-08

申请号：US13804691

申请日：2013-03-14

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Yuichi Suzuki ,  Takafumi Motoki ,  Toshihiko Kaneko ,  Mamoru Takaishi ,  Tasuku Ishida ,  Yoichi Kita ,  Kunitoshi Takeda ,  Noboru Yamamoto ,  Afzal Khan ,  Paschalis Dimopoulos

IPC: A61K31/542

CPC classification number: A61K31/542 ,  C07D279/08 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D513/04

Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

公开(公告)号：US20190231720A1

公开(公告)日：2019-08-01

申请号：US16260350

申请日：2019-01-29

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Keigo Tanaka ,  Tasuku Ishida ,  Masayuki Miyano ,  Raku Shinkyo

IPC: A61K31/166 ,  A61P19/10 ,  A61P29/00 ,  A61P7/06

CPC classification number: A61K31/166 ,  A61P7/06 ,  A61P19/10 ,  A61P29/00 ,  C07C233/73 ,  C07C235/60

Abstract: The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with a C1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C1-6 alkyl group.

公开(公告)号：US08946211B2

公开(公告)日：2015-02-03

申请号：US13804691

申请日：2013-03-14

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yuichi Suzuki ,  Takafumi Motoki ,  Toshihiko Kaneko ,  Mamoru Takaishi ,  Tasuku Ishida ,  Yoichi Kita ,  Kunitoshi Takeda ,  Noboru Yamamoto ,  Afzal Khan ,  Paschalis Dimopoulos

IPC: C07D513/02 ,  A61K31/542

CPC classification number: A61K31/542 ,  C07D279/08 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D513/04

Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

公开(公告)号：US10406126B2

公开(公告)日：2019-09-10

申请号：US16260350

申请日：2019-01-29

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Keigo Tanaka ,  Tasuku Ishida ,  Masayuki Miyano ,  Raku Shinkyo

IPC: C07C233/73 ,  C07C235/60 ,  A61K31/166 ,  A61P7/06 ,  A61P29/00 ,  A61P19/10

Abstract: The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with a C1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C1-6 alkyl group.